Documento completo  |  Capítulo completo  |  Expandir índice  |  Versión HTML imprimible
Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. PATENTABLE SUBJECT MATTER
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Abrir esta carpeta y ver su contenidoIV. PATENTABILITY REQUIREMENTS
Abrir esta carpeta y ver su contenidoV. SPECIAL CASES IN PHARMACEUTICALS
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Abrir esta carpeta y ver su contenidoVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER


Drafts of this document at different stages of elaboration have been reviewed by: J. H. Reichman (Vanderbilt University, USA), Trevor Cook (United Kingdom), B.K. Keayla (India), and Ian Roberts (South Africa). Comments were also made by R. Kaukab (South Centre), S. Zarrilli (UNCTAD), B.L. Das (India), James Love (Consumer Project on Technology, Washington D.C.) and Bas van der Heide (Health Action International).

A preliminary presentation and discussion of an earlier version of the text was made in a parallel meeting to the WTO Ministerial Meeting in Seattle in December 1999. It was also reviewed by an expert group, co-sponsored by the Department of Essential Drugs of the World Health Organization and the Rockefeller Foundation. The members of the expert group which met on 12 May 2000 in New York, were: Sakiko Fukuda-Parr, Director, Human Development Report Office, United Nations Development Programme; Richard O. Laing, Associate Professor of International Health, Boston University School of Public Health; Frederick M. Abbott, Visiting Professor of Law, University of California at Berkeley School of Law; Joan Archer and Ruth Gana Okediji, Technical Co-operation for Developing Countries Programme, United Nations Development Programme; Jayashree Watal, Institute of International Economics, Washington D.C.; and German Velasquez, Coordinator, Drug Action Programme, Department of Essential Drugs and Medicines Policy, World Health Organization.

The author is grateful for their valuable comments and inputs, and also for the support from the Rockefeller Foundation for the preparation of this document.

Any views expressed are the views of the author and do not necessarily reflect the views of the Rockefeller Foundation or of the World Health Organization. The author is solely responsible for this final text.

This document has been edited by Robert Weissman.


Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019